Cargando…
Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure
SIMPLE SUMMARY: This review compiles our current knowledge of one of the main pathways activated by tumors to escape immune attack. Indeed, it integrates the current understanding of how tumor-derived circulating galectins affect the elicitation of effective anti-tumor immunity. It focuses on severa...
Autores principales: | Laderach, Diego José, Compagno, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469970/ https://www.ncbi.nlm.nih.gov/pubmed/34572756 http://dx.doi.org/10.3390/cancers13184529 |
Ejemplares similares
-
Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity
por: Corapi, Enrique, et al.
Publicado: (2018) -
Inhibition of galectins in cancer: Biological challenges for their clinical application
por: Laderach, Diego José, et al.
Publicado: (2023) -
Delineating the "galectin signature" of the tumor microenvironment
por: Compagno, Daniel, et al.
Publicado: (2013) -
Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials
por: Compagno, Daniel, et al.
Publicado: (2020) -
Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers
por: Laderach, Diego J., et al.
Publicado: (2013)